Themis Medicare Ltd is Rated Sell

Current Rating and Its Implications for Investors

The 'Sell' rating assigned to Themis Medicare Ltd indicates a cautious stance for investors considering this stock. This recommendation suggests that the stock may underperform relative to the broader market or sector peers in the near to medium term. Investors should carefully weigh the risks highlighted by the company’s financial and operational metrics before making investment decisions.

Quality Assessment: Average Operational Strength Amidst Challenges

As of 20 September 2026, Themis Medicare Ltd’s quality grade is assessed as average. While the company operates within the Pharmaceuticals & Biotechnology sector, which generally demands strong research and development capabilities and robust product pipelines, Themis Medicare’s recent performance reveals significant operational challenges. The company’s ability to service its debt is notably weak, with a Debt to EBITDA ratio standing at an alarming 100.09 times. This indicates a substantial burden of debt relative to earnings before interest, taxes, depreciation, and amortisation, raising concerns about financial stability.

Moreover, the operating profit has declined sharply, with a negative annual growth rate of -194.65% over the past five years. Quarterly profit after tax (PAT) has also deteriorated significantly, registering a loss of ₹34.65 crores, which represents a staggering fall of -7080.2% compared to the previous four-quarter average. These figures highlight the company’s struggle to generate consistent profits and maintain operational efficiency.

Valuation: Risky Position Amid Negative Earnings

The valuation grade for Themis Medicare Ltd is currently classified as risky. The company’s negative EBITDA of ₹-41.97 crores signals ongoing operational losses, which adversely affect its valuation multiples. Despite the stock’s recent price appreciation—up 5.45% on the day and 61.04% over the past six months—the underlying fundamentals suggest caution. The stock’s one-year return is negative at -5.18%, reflecting the market’s tempered confidence in the company’s prospects.

Additionally, the stock is trading at valuations that are considered risky relative to its historical averages. This elevated risk is compounded by the fact that 43.39% of promoter shares are pledged, a factor that can exert downward pressure on the stock price during market downturns. The proportion of pledged shares has increased by 40.96% over the last quarter, signalling potential liquidity concerns and heightened risk for shareholders.

Financial Trend: Negative Momentum and Cash Constraints

The financial trend for Themis Medicare Ltd is negative, reflecting deteriorating profitability and cash flow challenges. The company’s operating profit to interest coverage ratio is at a low of -17.59 times, indicating that earnings are insufficient to cover interest expenses. Cash and cash equivalents are also at a low level of ₹9.15 crores as of the half-year period, limiting the company’s ability to fund operations or invest in growth initiatives without resorting to additional borrowing or equity dilution.

Profitability has been under severe pressure, with profits falling by -103.4% over the past year. This negative trend underscores the company’s ongoing difficulties in reversing losses and achieving sustainable growth.

Technical Outlook: Bullish Signals Amid Fundamental Concerns

Interestingly, the technical grade for Themis Medicare Ltd is bullish, suggesting that recent price movements and chart patterns indicate positive momentum in the stock’s market performance. The stock has delivered a one-month return of +17.66% and a three-month return of +22.21%, signalling short-term investor interest and potential for price appreciation.

However, investors should interpret this technical optimism with caution given the company’s fundamental weaknesses. While technical indicators may offer opportunities for short-term trading gains, the underlying financial and operational challenges present significant risks for long-term investors.

Investor Considerations and Outlook

For investors, the 'Sell' rating on Themis Medicare Ltd reflects a combination of operational difficulties, financial strain, and valuation risks. The company’s high debt levels and negative earnings trend suggest that it faces significant headwinds in returning to profitability and generating shareholder value. The elevated proportion of pledged promoter shares adds an additional layer of risk, particularly in volatile market conditions.

While the bullish technical signals may attract short-term traders, long-term investors should carefully evaluate the company’s fundamentals before committing capital. The average quality grade and negative financial trend imply that the company must address its operational inefficiencies and strengthen its balance sheet to improve its investment appeal.

In summary, the current 'Sell' rating by MarketsMOJO serves as a cautionary signal, advising investors to approach Themis Medicare Ltd with prudence and to monitor developments closely for any signs of financial recovery or strategic turnaround.

Company Profile and Market Context

Themis Medicare Ltd operates as a microcap entity within the Pharmaceuticals & Biotechnology sector. Despite the sector’s growth potential driven by innovation and healthcare demand, the company’s financial health and market performance have lagged behind expectations. As of 20 September 2026, the stock’s market behaviour shows mixed signals, with recent gains tempered by longer-term negative returns and fundamental weaknesses.

Summary of Key Metrics as of 20 September 2026

• Mojo Score: 45.0 (Sell Grade)
• Debt to EBITDA Ratio: 100.09 times
• Operating Profit Growth (5 years): -194.65% annually
• Quarterly PAT: ₹-34.65 crores
• Negative EBITDA: ₹-41.97 crores
• Promoter Shares Pledged: 43.39%
• Stock Returns: 1D +5.45%, 1M +17.66%, 6M +61.04%, 1Y -5.18%

These figures collectively underpin the current rating and provide a comprehensive view of the stock’s risk and return profile.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →